The Administration’s continued pursuit to strike down the Affordable Care Act (ACA) in the courts openly undermines affordable health insurance coverage during the pandemic, threatening our public health response and economic recovery. The COVID-19 pandemic has caused unprecedented and widespread damage to our health and economy Since January, more than 3 million people have been […]
The Pharmaceutical Pricing Debate in the U.S.: Comparing the Current U.S. Situation to Germany
John Rother President, National Coalition on Health Care Introduction The price of pharmaceuticals has been a top policy issue in the U.S., especially since the introduction of the $1000 per pill Hep C drug Sovaldi in 2017. Drug prices are a top concern for Americans going into the fall elections. The issue is driven by […]
H.R. 1425: The Patient Protection and Affordable Care Enhancement Act
House Democrats unveiled H.R. 1425 which would expand and protect key elements of the Affordable Care Act (ACA). Key provisions of H.R. 1425 include expanding subsidies and eligibility requirements for state-level exchanges. Importantly, states would have the ability to expand premium tax credits beyond 400% of the federal poverty line. H.R. 1425 also fixes the […]
Stressed Health Care System Today Could Result in Better Care Tomorrow
Today’s health care institutions are stretched to capacity and beyond by the COVID-19 crisis. But like physical exercise, it’s possible that this stress can lead us to a stronger system longer-term. This depends, of course, on how we respond to the shortcomings revealed by our slow responses to the pandemic.From my decades in health policy, […]
Has “Value” in Health Care Stagnated?
The future of value-based purchasing (VBP) is uncertain. Current models have theoretical promise, but critics point to minimal achievements. Despite the rhetoric around paying for value over volume, the percent of health care spending involved in pay-for-performance contracts has stagnated or declined. In addition, the polled enthusiasm among health care industry leaders for value-based purchasing is declining. […]
Multi-stakeholder Coalition Applauds Legislation to Provide Affordable Health Care to All Americans
Washington, DC – Yesterday, Speaker Nancy Pelosi (D-CA), Majority Leader Steny Hoyer (D-MD), Energy & Commerce Committee Chairman Frank Pallone Jr. (D-NJ), Ways & Means Committee Chairman Richard Neal (D-MA), and Education & Labor Committee Chairman Bobby Scott (D-VA) released a joint statement announcing that H.R. 3, the Lower Drug Costs Now Act, will come to a floor vote next week. The National Coalition on Health Care supports H.R. 3 to lower prescription drug prices and urges its swift passage to the U.S. Senate. […]
NCHC Writes Letter to Senator Alexander on Health Care Costs
On February 28th, NCHC wrote a letter to the Senate HELP Committee addressed to Senator Alexander. The letter was in response to a request from Senator Alexander asking for policy recommendations to address the rising costs of health care. You can read the entire letter here.
The German Pharmaceutical Model: Could it Work in the U.S.?
As drug prices continue to rise, policymakers debate drug pricing reform. The United States spends more on prescription drugs per capita than any other developed country. For example, Germany spends an average of $685 on retail prescription drugs per capita, while the United States spends over $1,000. Yet, Germany has a similar health care system […]
NCHC Statement on CARES 2.0 Act
Yesterday, negotiations over a fourth major COVID-19 relief package began in earnest after the Senate released the Health, Economic Assistance, Liability Protection and Schools (HEALS) Act. The National Coalition on Health Care (NCHC) applauds some elements of the bill, including critical funding for schools and nursing homes, which is necessary for both our economic recovery […]
NCHC: Drug Pricing Primer
High prescription drug prices contribute to high total health care costs in the United States. Prices in the United States are higher than any other developed country, outpacing the effects of volume, types of drugs, or population size on total drug spending. Retail prescription drugs accounted for 9% of the $3.6 trillion (17.7% of GDP) […]
NCHC Statement on the Trump Administration’s Executive Orders
The National Coalition on Health Care (NCHC) strongly opposes theAdministration’s approach to address drug pricing through the executive orders released today. The executive orders rightly recognize the urgency of addressing drug prices, but we encourage the White House to pursue more comprehensive options proposed by the House and Senate. “Specialty and many branded drugs have […]
- 1
- 2
- 3
- …
- 79
- Next Page »